Geron CorporationOrganisationTrialsStudy to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Phase 2/3Active, not recruiting289 people6 Nov 2015clinicaltrials.gov